Rolf Fendel

Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial

Peter G. Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana‐Arri et al. · The Lancet Infectious Diseases · 2021 · 170 citations · Full text

Immune response to SARS-CoV-2 variants of concern in vaccinated individuals

Matthias Becker, Alex Dulovic, Daniel Junker et al. · Nature Communications · 2021 · 160 citations · Full text

Vaccination, Vaccine Safety, Rbd Mutants +15

Safety and immunogenicity of an mRNA-lipid nanoparticle vaccine candidate against SARS-CoV-2

Peter G. Kremsner, Philipp Mann, Arne Kroidl et al. · Wiener klinische Wochenschrift · 2021 · 130 citations · Full text

Phase 1 Assessment of the Safety and Immunogenicity of an mRNA- Lipid Nanoparticle Vaccine Candidate Against SARS-CoV-2 in Human Volunteers

Peter G. Kremsner, Philipp Mann, Jacobus J. Bosch et al. · 2020 · 103 citations · Full text

Candidate Vaccine Cvncov, Viral Immunity, Immunology +17

Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon

Benjamin Mordmüller, Katja Szywon, Benedikt Greutélaers et al. · Vaccine · 2010 · 68 citations · Full text

Vaccination, Vaccine Safety, Vaccine Development +8